secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0001437749-25-006559
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity announces VA-funded Phase 2 trial of stenoparib + temozolomide in recurrent SCLC
--------------------------------------------------------------------------------

- Phase 2 trial of stenoparib (dual PARP/Wnt inhibitor) plus temozolomide for recurrent SCLC, fully funded by VA.
- Trial expects ~65 patients across 11 VA medical centers; initial safety lead-in to set recommended dose.
- Cash position supports operations into 2026; VA funding does not affect financial outlook or share repurchase plan.
- Stenoparib crosses blood-brain barrier, potentially treating brain metastases common in SCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925006559/0001437749-25-006559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925006559/allr20250306_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-006559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer